<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        175-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEFFIX 5MG\ML ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIVUDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        77.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Zeffix is used to treat hepatitis B.</strong></p><p>Zeffix is a type of medicine known as an antiviral.&nbsp; It belongs to a group of medicines called <em>nucleoside analogue reverse transcriptase inhibitors </em>(NRTIs).&nbsp;</p><p>Zeffix does not completely cure hepatitis B infection; it reduces the amount of virus in your body, and keeps it at a low level. However, this may stop your hepatitis B disease progressing and causing serious damage to your liver.</p><p>Not everyone responds to treatment with Zeffix in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take Zeffix</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_24329dce-06f6-4537-8d98-0617c10763a0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;&nbsp;&nbsp; if you&rsquo;re <strong>allergic </strong>(<em>hypersensitive</em>) to lamivudine or any of the other ingredients of Zeffix (listed in Section 6)</p><p>&egrave; <strong>Check with your doctor </strong>if you think this applies to you.</p><p><strong>Take special care with Zeffix</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_10bf6fbf-237c-4de6-815d-d961553b2826 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Before you take Zeffix your doctor needs to know:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>kidney </strong><strong>disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medications for the treatment of HIV infection</p><p>&egrave;&nbsp;&nbsp;&nbsp; <strong>Check with your doctor </strong>if you think any of these may apply to you.&nbsp; Your doctor may need to adjust your dose, or Zeffix may not be suitable for you.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop taking </strong><strong>Zeffix</strong> without your doctor&rsquo;s advice, as your hepatitis may get worse. When you stop taking Zeffix your doctor will monitor you for at least four months to check for any problems. This will mean taking blood samples to check for any abnormal liver enzyme levels.</p><p><strong>Protect other people</strong></p><p>Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). Zeffix will not stop you passing Hepatitis B infection on to other people. To protect other people from becoming infected with Hepatitis B:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use a condom</strong> when you sex (of any kind, including oral sex).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Don&rsquo;t risk blood transfer</strong> &mdash; for example, don&rsquo;t share needles.</p><p>&nbsp;</p><p><strong>Zeffix contains sugar</strong></p><p>If you are a diabetic, please note that each 100&nbsp;mg dose (or each 20&nbsp;ml) of Zeffix contains 4&nbsp;g of sugar<strong>. </strong></p><p><strong>Other medicines and Zeffix</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e1b0c4e1-e516-4e12-b129-5cf00cb13961 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Tell your doctor or pharmacist if you&rsquo;re taking any other medicines,</strong> if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p>Some medicines may affect how Zeffix works, or make it more likely that you&rsquo;ll have side effects. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing sorbitol, used regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trimethoprim-sulphamethoxazole (also known as co-trimoxazole), an <strong>antibiotic</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zidovudine or emtricitabine , used to treat<strong> HIV infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alpha interferon<strong>,</strong> used to treat <strong>viral</strong> <strong>infections</strong></p><p>&egrave;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist </strong>if you are taking any of these.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_01fc4828-a72a-4f87-94c5-904229a942b6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are<strong> pregnant</strong> or <strong>think you could be, </strong>or if you are <strong>planning to become pregnant:</strong>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor</strong> about the risks and benefits of taking Zeffix.</p><p>The ingredients in Zeffix can pass into breast milk.&nbsp; If you are breast-feeding, you must check with your doctor before you take Zeffix.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take Zeffix exactly as your doctor has told you to</strong>. Check with your doctor or pharmacist if you&rsquo;re not sure.</p><p><strong>How much to take</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_aed6d93e-728b-4096-b551-6d6da973ba44 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Adults and adolescents</strong></p><p><strong>The usual dose</strong> of Zeffix is 100&nbsp;mg a day.</p><p><strong>Children from 2 to 11 years old</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f47a2f60-01f1-4ef6-9c49-c9401bd3f992 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:12.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Your doctor will decide on the correct dose of Zeffix for your child, depending on the size of your child.<!--[if supportFields]><span style='mso-bidi-font-size:12.0pt;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b899584b-2112-4443-a429-a1091ee6d93b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:12.0pt;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>The usual dose</strong> of Zeffix is 3&nbsp;mg/kg once a day, up to a maximum of 100&nbsp;mg a day.</p><p><strong>Patients with kidney problems </strong></p><p>If you have a kidney problem, your doctor may alter your dose.</p><p>&egrave; <strong>Talk to your doctor </strong>if this applies to you.<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9a6bf171-8f4d-4076-b467-1d8feda44ad8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Patients who also have HIV infection</strong></p><p>Lamivudine can also be used to treat HIV infection.&nbsp; Talk to your doctor if you have HIV infection.&nbsp; Your doctor may treat you with a higher dose of lamivudine, usually 150&nbsp;mg twice a day, as the lower dose of 100&nbsp;mg lamivudine is not enough to treat HIV infection.</p><p>&egrave; <strong>Talk to your doctor </strong>if this applies to you.<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8f88ea85-5d22-452f-82fb-021a64ffe272 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>How to take</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8404a3d7-b10b-485d-8be3-16c4212db7ed \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Use the oral dosing syringe supplied with the pack to measure the correct dose of Zeffix</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Remove the bottle cap</strong>. Keep it safely.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the bottle firmly. <strong>Push the plastic adapter into the neck of the bottle</strong>.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Insert the syringe</strong> firmly into the adapter.</p><p>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle upside down.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pull out the syringe plunger</strong> until the syringe contains the first part of your full dose.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle the correct way up. <strong>Remove the syringe</strong> from the adapter.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Put the syringe into your mouth,</strong> placing the tip of the syringe against the inside of your cheek. <strong>Slowly push the plunger in,</strong> allowing time to swallow. <strong>Don&rsquo;t </strong>push too hard and squirt the liquid into the back of your throat or you may choke.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Repeat steps 3 to 7</strong> in the same way until you have taken your whole dose. <em>For example, if your dose is 15&nbsp;ml, you need to take one and a half syringe-full of medicine.</em></p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take the syringe out of the bottle</strong> and <strong>wash</strong> it thoroughly in clean water. Let it dry completely before you use it again.</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp; <strong>Close the bottle tightly</strong> with the cap, leaving the adaptor in place.</p><p>&nbsp;</p><p>Zeffix can be taken with or without food.</p><p><strong>If you forget to take Zeffix</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a53d40f2-69fc-4f2e-b0cd-4f52b5f8645a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Don&rsquo;t take a double dose</strong> to make up for a missed dose. Just take it as soon as you remember.<br /><strong>If you are not sure what to do, </strong>ask your doctor or pharmacist</p><p><strong>If you take too much Zeffix</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a57d481f-19d8-4709-9899-b2c384e9209b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take<em> </em>too much Zeffix, <strong>contact your doctor or pharmacist for advice.</strong> If possible, show them the Zeffix pack.</p><p><strong>Don&rsquo;t stop Zeffix without advice</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f0f57fc0-5990-474d-8f81-604003f1b3bf \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Take Zeffix for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to as your hepatitis B may get worse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Very common side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e3cd769f-860e-4c9f-a715-3e0e164188a2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>more than</strong> <strong>1 in 10 people: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the level of liver enzymes</p><p>&nbsp;</p><p><strong>Common side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f63a1351-c28a-4d7b-85d2-cbc0e6462608 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10</strong> <strong>people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the level of enzymes produced in the muscles (<em>creatine phosphokinase</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle disorders, (including muscle pain and cramps)</p><p>&nbsp;</p><p><strong>Very rare side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3d25915f-6a9a-455e-80d4-1afa94732415 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10,000 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in the number of cells involved in blood clotting <em>(thrombocytopenia)</em></p><p>&egrave; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep Zeffix out of the sight and reach of children.</strong></p><p>Don&rsquo;t take Zeffix after the expiry date shown on the carton.</p><p>Store Zeffix below 25&nbsp;&deg;C (77&nbsp;&deg;F).</p><p>Throw away the bottle one month after first opening it, but don&rsquo;t dispose of the medicine in your wastewater or your household rubbish. Ask your pharmacist how to dispose of medicines no longer required.&nbsp; This will help to protect the environment.<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active ingredients: </strong></p><p>Lamivudine 5 mg in each 5 ml solution</p><p><strong>Other non-active ingredients: </strong></p><p>Sucrose (20% w/v). (see Warnings and Precautions)</p><p>Methyl parahydroxybenzoate.</p><p>Propyl parahydroxybenzoate.</p><p>Citric acid (anhydrous).</p><p>Propylene glycol.</p><p>Sodium citrate.</p><p>Artificial strawberry flavour.</p><p>Artificial banana flavour.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cartons containing 240 ml ZEFFIX oral solution 5 mg/ml in an opaque, white high-density polyethylene (HDPE) bottle with a polypropylene child resistant closure. The pack includes a clear oral dosing syringe and an adapter.





Not all presentations are available in every country.



ZEFFIX is a trademark owned by or licensed to the GSK group of companies.

© 2021 GlaxoSmithKline, all rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Bora Pharmaceutical Services Inc. Mississauga, Canada</p><p>&nbsp;</p><p><strong>Packed by:</strong></p><p>Bora Pharmaceutical Services Inc. Mississauga, Canada</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: GDS17
Date of issue:  06 July 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يُستخدم زيفيكس لعلاج التهاب الكبد </strong><strong>B</strong><strong>.</strong></p><p dir="RTL">زيفيكس هو أحد أنواع الأدوية المعروفة باسم مضاد الفيروسات. وينتمي إلى مجموعة من الأدوية تُسمى <em>مثبطات إنزيم المنتسخة العكسية المضاهئ للنوكليوزيد (</em><em>NRTIs</em><em>).</em></p><p dir="RTL">لا يقضي زيفيكس تمامًا على عدوى التهاب الكبد B؛ فهو يقلل من كمية الفيروس في الجسم، ويحافظ على بقاء الفيروس بمستوى منخفض. لكنه قد يمنع تقدم مرض التهاب الكبد B وما يُسببه من أضرار بالغة للكبد.</p><p dir="RTL">وتتفاوت استجابة المرضى للعلاج بدواء زيفيكس. وسوف يتابع الطبيب فعالية العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول زيفيكس</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_abef0647-e1cc-4c6b-982e-8bf23f97b640
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>التحسس</strong> (فرط الحساسية) تجاه لاميفودين أو أيٍّ من المكوِّنات الأخرى لدواء زيفيكس (المذكورة في القسم 6)</p><p dir="RTL"><strong>&aacute;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>راجع الطبيب </strong>إذا كنت تعتقد أن هذه الحالة تنطبق عليك.</p><p dir="RTL"><strong>توخ الحذر الشديد عند تناول زيفيكس</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_834ef934-4301-49b3-beca-75d256732483
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قبل تناول زيفيكس، يجب إبلاغ الطبيب إذا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق لك في أي وقت الإصابة <strong>بأمراض الكُلى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية في الوقت الحالي لمعالجة عدوى فيروس نقص المناعة البشرية (HIV)</p><p dir="RTL">&aacute;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>راجع الطبيب المعالج </strong>إذا كنت تعتقد أن هذه الحالة تنطبق عليك. قد يضطر الطبيب إلى تعديل الجرعة أو ربما يكون زيفيكس غير مناسب لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول زيفيكس</strong> دون استشارة الطبيب، لاحتمال تفاقم الالتهاب الكبدي لديك. عند التوقف عن تناول زيفيكس، سوف يتابع الطبيب حالتك لمدة أربعة شهور على الأقل للتحقق من وجود أي مشاكل. وهذا يعني سحب عينات الدم للتحقق من ظهور أي مستويات غير طبيعية لإنزيمات الكبد.</p><p dir="RTL"><strong>وقاية الآخرين</strong></p><p dir="RTL">تنتشر عدوى التهاب الكبد B عن طريق الاتصال الجنسي بشخص مُصاب بالعدوى أو عبر نقل الدم المُلوث (على سبيل المثال، مشاركة إبر الحقن). لا يمنع زيفيكس انتقال عدوى التهاب الكبد B منك للآخرين. لوقاية الآخرين من الإصابة بالتهاب الكبد B:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استخدم واقٍ ذكريّ </strong>عند ممارسة الجنس (من أي نوع، بما في ذلك الجنس الفموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تجنب التعرض لمخاطر نقل الدم</strong> &mdash; على سبيل المثال، لا تشارك الغير في الإبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زيفيكس على السكر</strong></p><p dir="RTL">إذا كنت تعاني من مرض السكر، يُرجى ملاحظة أن كل جرعة 100 ملغم (أو كل 20 مل) من زيفيكس تحتوي على 4 جم من السكر.<strong> </strong></p><p dir="RTL"><strong>زيفيكس والتداخلات الدوائية مع الأدوية الأخرى</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_8a9547f3-68c8-47a1-88b2-dce37877d793
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>أبلغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى في الوقت الحالي</strong>، أو تناولت بعض الأدوية مؤخرًا أو عند الشروع في تناول أدوية جديدة. ويشمل ذلك الأدوية التي تُصرف بدون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على فاعلية زيفيكس أو تزيد من احتمال ظهور آثار جانبية. وتشمل تلك الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية (عادة السوائل) التي تحتوي على السوربيتول، والتي تستخدم بانتظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريميثوبريم/سلفاميثوكسازول (يُعرف أيضًا باسم كو-تريموكسازول، وهو<strong> مضاد حيوي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين أو امتريسيتابين، يُستخدم لعلاج <strong>عدوى فيروس نقص المناعة البشرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفا إنترفيرون، يُستخدم لعلاج حالات <strong>العدوى الفيروسية</strong></p><p dir="RTL"><strong>&aacute;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أبلغ الطبيب أو الصيدلاني </strong>في حال تناول أي من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_c61a6ec8-f903-485d-a538-3c55d6867404
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كنتِ <strong>حاملًا </strong>أو <strong>تعتقدين أنك حامل، </strong>أو تنوين <strong>الحمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استشيري الطبيب</strong> بشأن المخاطر والفوائد المترتبة على تناول زيفيكس.</p><p dir="RTL">يمكن أن تتسرب مكونات زيفيكس إلى حليب الأم. إذا كنتِ مُرضِعًا، عليك استشارة الطبيب قبل استخدام زيفيكس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>احرص دائمًا على تناول زيفيكس وفقًا لتعليمات الطبيب.</strong> راجع الطبيب أو الصيدلي إذا كنت غير متأكد من كيفية تناول الدواء.</p><p dir="RTL"><strong>الجرعة</strong><!--[if supportFields]><b><span lang=AR-SA
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_94225a98-e1b8-4fcf-90fe-391b467e7914
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون والمراهقون</strong></p><p dir="RTL"><strong>الجرعة المعتادة</strong> من زيفيكس هي 100 مجم في اليوم.</p><p dir="RTL"><strong>الأطفال الذين تتراوح أعمارهم من 2 إلى 11 سنة</strong><!--[if supportFields]><b><span lang=AR-SA
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='mso-bidi-font-size:12.0pt'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='mso-bidi-font-size:12.0pt'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='mso-bidi-font-size:12.0pt'>VAULT_ND_187d94f1-47ad-4358-ae74-00c7466d3a51
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:12.0pt'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">سوف يُحدد الطبيب جرعة زيفيكس المناسبة لطفلك بحسب وزنه.<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-bidi-font-size:12.0pt'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:12.0pt'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:
12.0pt'>VAULT_ND_79a7f8a5-cc06-42b2-a8f4-289f272e7d86 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:12.0pt'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>الجرعة المعتادة </strong>من زيفيكس هي 3 مجم/كجم مرة واحدة يوميًا حتى 100 مجم في اليوم كحد أقصى.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكُلى </strong></p><p dir="RTL">إذا كنت تعاني من مشكلة في الكُلى، فقد يلجأ الطبيب إلى تعديل الجرعة.</p><p dir="RTL"><strong>&aacute;</strong><strong> </strong><strong>&lrm;</strong><strong>استشر الطبيب </strong>إذا كانت هذه الحالة تنطبق عليك.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:12.0pt;color:black'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
12.0pt;color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:12.0pt;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:12.0pt;
color:black'>VAULT_ND_45d11359-2072-4c01-83ed-b40d67abd9c9 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:12.0pt;
color:black'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:12.0pt;color:black'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون أيضًا من عدوى فيروس نقص المناعة البشرية</strong></p><p dir="RTL">يمكن أيضًا استخدام لاميفودين لعلاج عدوى فيروس نقص المناعة البشرية. استشر الطبيب إذا كنت مصابًا بعدوى فيروس نقص المناعة البشرية. قد يُعالجك الطبيب بجرعة أعلى من لاميفودين، وتكون عادة 150 مجم مرتين في اليوم، لأن جرعة لاميفودين الأقل التي تبلغ 100 مجم غير كافية لعلاج عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL"><strong>&aacute;</strong><strong> </strong><strong>&lrm;</strong><strong>استشر الطبيب </strong>إذا كانت هذه الحالة تنطبق عليك.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:12.0pt;color:black'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
12.0pt;color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:12.0pt;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:12.0pt;
color:black'>VAULT_ND_540c1fdf-a9aa-4ed1-af3b-a454c0efbc4e \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:12.0pt;
color:black'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:12.0pt;color:black'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول الجرعة</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_dfddefef-cee5-4d30-9857-821ca31e1436
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استخدم محقنة تحديد الجرعة الفموية التي تتوفر مع العبوة لقياس الجرعة الصحيحة من زيفيكس.</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>افتح غطاء القارورة</strong>. حافظ على سلامته.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك القارورة بإحكام. <strong>اضغط على الوصلة المهيئة البلاستيكية إلى داخل عنق القارورة</strong>.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أدخل المحقنة</strong> بإحكام في الوصلة.</p><p dir="RTL">4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب القارورة رأسًا على عقب.</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اسحب مكبس المحقنة إلى الخارج</strong> حتى تحتوي المحقنة على الجزء الأول من الجرعة الكاملة.</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعد القارورة إلى وضعها الصحيح من الأسفل إلى الأعلى. <strong>افصل المحقنة</strong> من الوصلة.</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ضع المحقنة في فمك،</strong> بحيث يكون طرف المحقنة مقابل بطانة الوجنة. <strong>اضغط على المكبس ببطء</strong>، بحيث تتيح مُهلة للبلع. <strong>لا </strong>تضغط بقوة شديدة وتبُخ السائل إلى مؤخرة الحلق حتى لا تتعرض للاختناق.</p><p dir="RTL">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كرر الخطوات من 3 إلى 7</strong> باتباع الطريقة نفسها حتى تنتهي من تناول جرعتك كاملة. <em>على سبيل المثال، إذا كانت الجرعة 15 مل، فإنك تحتاج إلى تناول ملء المحقنة مرة ونصف من الدواء.</em></p><p dir="RTL">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخرج المحقنة من القارورة</strong> ثم <strong>اغسلها</strong> جيدًا بالماء النقي. اتركها حتى تجف تمامًا قبل استخدامها مرة أخرى.</p><p dir="RTL">10.&nbsp;&nbsp;&nbsp;&nbsp; <strong>أغلق القارورة بإحكام</strong> بالغطاء واترك الوصلة في موضعها.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL">يمكن تناول زيفيكس مع الطعام أو بدونه.</p><p dir="RTL"><strong>في حال نسيان تناول زيفيكس</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_4df46910-9118-41e2-90f6-f697be2fd6cb
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>لا تتناول جرعة مضاعفة </strong>لتعويض الجرعة المنْسيّة. وتناولها فقط حالما تتذكر.<br /><strong>إذا كنت غير متأكد من الإجراء الواجب اتخاذه، </strong>استشر الطبيب أو الصيدلي.</p><p dir="RTL"><strong>في حال تناول جرعة زائدة من زيفيكس</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_be30d68e-06e8-414a-8d97-3e336534ce1f
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">عند تناول<em> </em>عدد كبير من أقراص زيفيكس، <strong>اتصل بالطبيب أو الصيدلي للاستشارة.</strong> ويُفضل أن تُري عبوة زيفيكس للطبيب أو الصيدلي إن أمكن.</p><p dir="RTL"><strong>لا توقف تناول زيفيكس دون استشارة</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_caf07131-01a6-4e6a-a8f1-4804df75b471
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تناول زيفيكس طوال المدة التي يُحددها الطبيب. لا توقف تناول الدواء ما لم ينصحك الطبيب بذلك لاحتمال تفاقم التهاب الكبد B لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية الأكثر شيوعًا</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_70eec5a7-e09c-4574-a1d2-fe8501dfe19c
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قد تُصيب تلك الآثار <strong>أكثر &rlm;من مريض واحد من بين كل 10</strong><strong> مرضى: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في مستوى إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_cd687200-e553-427f-93f6-45ccfe3502ff
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قد تُصيب تلك الآثار <strong>مريضًا واحدًا من بين كل 10 مرضى:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في مستوى الإنزيمات التي تُنتَج في العضلات (<em>فسفوكيناز الكرياتين</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات العضلات، (بما في ذلك آلام العضلات وتقلص العضلات)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشديدة النُدرة</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:
major-latin;mso-bidi-theme-font:major-latin'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-size:13.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;
mso-bidi-theme-font:major-latin'>VAULT_ND_bb5d5157-248f-429a-8c1c-745b489839c8
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-theme-font:major-latin'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قد تُصيب تلك الآثار <strong>مريضًا واحدًا من بين كل 10000 مريض:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق في الأنسجة العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الخلايا المشاركة في تجلط الدم (نقص الصفائح الدموية)</p><p dir="RTL"><strong>&aacute;</strong><strong> أبلغ الطبيب أو الصيدلي</strong> إذا أصبح أي من الآثار الجانبية المذكورة <strong>مزعجًا أو أشد وطأة</strong>، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفظ زيفيكس بعيدًا عن مرأى ومتناول الأطفال.</strong></p><p dir="RTL">لا تتناول زيفيكس بعد تاريخ انتهاء الصلاحية المُدَّون على العبوة.</p><p dir="RTL">يُخَزن زيفيكس في درجة حرارة أقل من 25 &deg;م (77 &deg;ف).</p><p dir="RTL">تخلص من القارورة بعد شهر واحد من فتحها للمرة الأولى، ولكن لا تتخلص من الدواء في مياه الصرف أو المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من فائض الأدوية. فهذا من شأنه أن يساعد على حماية البيئة.<em> </em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المكوِّنات الفعَّالة: </strong></p><p dir="RTL">لاميفودين 5 مجم في كل 5 مل من المحلول</p><p dir="RTL"><strong>المكوِّنات الأخرى غير الفعَّالة: </strong></p><p dir="RTL">سكروز (20% و/ح) (راجع &quot;التحذيرات والاحتياطات&quot;)</p><p dir="RTL">بارا هيدروكسي بنزوات الميثيل</p><p dir="RTL">بارا هيدروكسي بنزوات البروبيل</p><p dir="RTL">حمض سيتريك (لا مائي)</p><p dir="RTL">بروبيلين جليكول.</p><p dir="RTL">سترات الصوديوم.</p><p dir="RTL">نكهة فراولة صناعية.</p><p dir="RTL">نكهة موز صناعية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">علب كرتونية تحوي 240 مل <strong><em>زيفيكس</em></strong> محلول مائي 5 مجم/مل في قارورة بيضاء مُعْتمة من البولي إيثيلين عال الكثافة (HDPE) مزودة بغطاء من البولي بروبيلين مقاوم للفتح من قبل الأطفال. وتحوي العبوة محقنة تجريع فموي شفافة ووصلة مهايئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوفر بعض الأحجام في بعض الدول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>زيفيكس</em></strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL">&copy; 2021 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">بورا فارماسيوتيكالز سيرفيس إنك ، ميسيساكا ، كندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المُعبئة:</strong></p><p dir="RTL">بورا فارماسيوتيكالز سيرفيس إنك ، ميسيساكا ، كندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المالكة لحق التسويق </strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة * ، جدة، المملكة العربية السعودية</p><p dir="RTL">*إحدى شركات جلاكسو سميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم النسخة: GDS17
تاريخ الإصدار: 6 يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZEFFIX  Oral Solution lamivudine 5 mg/ml.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamivudine 5 mg/ml.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZEFFIX</em> is indicated for the treatment of patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZEFFIX</em> can be taken with or without food.</p><p>&nbsp;</p><p>Patient compliance should be monitored while on <em>ZEFFIX</em> therapy.</p><p>&nbsp;</p><p>Discontinuation of <em>ZEFFIX</em> may be considered in immunocompetent patients when HBeAg and/or HBsAg seroconversion occurs. Discontinuation may also be considered when loss of efficacy occurs, as indicated by recurrent signs of hepatitis.</p><p>&nbsp;</p><p>If <em>ZEFFIX</em> is discontinued, patients should be periodically monitored for evidence of recurrent hepatitis (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p>Discontinuation of treatment is not recommended in patients with decompensated liver disease. There are limited data regarding the maintenance of seroconversion long term after stopping treatment with <em>ZEFFIX</em>.</p><p>&nbsp;</p><p>ZEFFIX should be used in accordance with available official recommendations.</p><p>&nbsp;</p><p><em>ZEFFIX</em> oral solution is available for use in children and those patients for whom the tablets are inappropriate</p><p>&nbsp;</p><p>Populations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults and adolescents 12 years and older</strong></p><p>The recommended dosage of <em>ZEFFIX</em> is 100&nbsp;mg once daily.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children from two to eleven years</strong></p><p>The recommended dose is 3&nbsp;mg/kg once daily up to a maximum of 100&nbsp;mg daily.</p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children less than two years</strong></p><p>There are insufficient data available to propose specific dosage recommendations in this age group.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal impairment</strong></p><p>Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance. The dosage should therefore be reduced for patients with a creatinine clearance of less than&nbsp;50&nbsp;ml/min (<em>see Table 1 below</em>). The same percentage reduction in dose applies for children with renal impairment (<em>see Table 2</em>).</p><p><u>&nbsp;</u></p><p><u>Table 1&nbsp; Dosing recommendations &ndash; adults and adolescents 12 years and older.</u><!--[if supportFields]><u><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4b4ae1fe-054c-41be-97d1-c0182045a1ac \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-element:field-end'></span></u><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:663px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance ml/min</strong></p></td><td style="vertical-align:top"><p><strong>First dose of <em>ZEFFIX</em> oral solution</strong>&dagger;</p></td><td style="vertical-align:top"><p><strong>Maintenance dose once daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>30 to &lt;50&nbsp; </strong></p></td><td style="vertical-align:top"><p>20 ml (100 mg)</p></td><td style="vertical-align:top"><p>10 ml (50 mg)</p></td></tr><tr><td style="vertical-align:top"><p><strong>15 to &lt;30</strong></p></td><td style="vertical-align:top"><p>20 ml (100 mg)</p></td><td style="vertical-align:top"><p>5 ml (25 mg)</p></td></tr><tr><td style="vertical-align:top"><p><strong>5 to &lt;15 </strong></p></td><td style="vertical-align:top"><p>7 ml (35 mg)</p></td><td style="vertical-align:top"><p>3 ml (15 mg)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;5&nbsp; </strong></p></td><td style="vertical-align:top"><p>7 ml (35 mg)</p></td><td style="vertical-align:top"><p>2 ml (10 mg)</p></td></tr></tbody></table><p>&dagger; <em>ZEFFIX</em> oral solution containing 5mg/ml lamivudine.</p><p>&nbsp;</p><p><u>Table 2&nbsp; Dosing recommendations &ndash; children 2 to 11 years.</u><!--[if supportFields]><u><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a8786078-078e-4b08-8429-d13b7d751f9d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-element:field-end'></span></u><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:663px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance ml/min</strong></p></td><td style="vertical-align:top"><p><strong>First dose of <em>ZEFFIX</em> oral solution</strong>&dagger;<strong> </strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose once daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>30 to &lt;50&nbsp; </strong></p></td><td style="vertical-align:top"><p>3&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.5&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p><strong>15 to &lt;30</strong></p></td><td style="vertical-align:top"><p>3&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>0.75&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p><strong>5 to &lt;15 </strong></p></td><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>0.45&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg</p></td></tr></tbody></table><p>&dagger; ZEFFIX oral solution containing 5mg/ml lamivudine.</p><p>Data available in patients undergoing intermittent haemodialysis (less than or equal to 4h dialysis 2 to 3 times weekly), indicate that following the initial dosage reduction of <em>ZEFFIX</em> to correct for the patient&#39;s creatinine clearance, no further dosage adjustments are required while undergoing dialysis.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment</strong></p><p>Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that <em>ZEFFIX</em> pharmacokinetics are not significantly affected by hepatic dysfunction.</p><p>Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZEFFIX oral solution is contraindicated in patients with known hypersensitivity to ZEFFIX or to any ingredient of the preparations.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.</p><p>During initiation and maintenance of treatment patients should be monitored regularly by a physician experienced in the management of chronic hepatitis B.</p><p>&nbsp;</p><p>&nbsp;If ZEFFIX is discontinued or there is a loss of efficacy, some patients may experience clinical or laboratory evidence of recurrent hepatitis. Exacerbation of hepatitis has primarily been detected by serum ALT elevations, in addition to the re-emergence of HBV DNA. See Table 4 in Clinical Studies for more information regarding frequency of post treatment ALT elevations<em> </em>for more information regarding frequency of post treatment ALT elevations. Most events appear to have been self-limited. Fatalities are very rare and the causal relationship to discontinuation of ZEFFIX treatment is unknown.</p><p>&nbsp;</p><p>&nbsp;If ZEFFIX is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months for evidence of recurrent hepatitis; patients should then be followed as clinically indicated. For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of ZEFFIX treatment.</p><p>&nbsp;</p><p>&nbsp;In patients with moderate to severe renal impairment serum lamivudine concentrations (AUC) are increased due to decreased renal clearance, therefore the dose should be reduced for patients with a creatinine clearance of less than&nbsp;50&nbsp;ml/minute. (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p>&nbsp;Transplantation recipients and patients with advanced liver disease are at greater risk from active viral replication.&nbsp; Due to marginal liver function in these patients, hepatitis reactivation at discontinuation of ZEFFIX or loss of efficacy during treatment may induce severe and even fatal decompensation.&nbsp; It is recommended that these patients are monitored for parameters associated with hepatitis B, for liver and renal function, and for antiviral response during treatment.&nbsp; If treatment is discontinued for any reason, it is recommended that these patients are monitored for at least 6 months post cessation of treatment.&nbsp; Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored frequently, as appropriate.</p><p>&nbsp;</p><p>There are limited data on the use of <em>ZEFFIX</em> in patients receiving concurrent immunosuppressive regimes, including cancer chemotherapy.</p><p><br />In HBeAg positive or negative patients, the development of YMDD (tyrosine-methionineaspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels. In order to reduce the risk of resistance in patients receiving lamivudine monotherapy, a switch to or addition of an alternative agent without cross-resistance to lamivudine should be considered if serum HBV DNA remains detectable at or beyond 24 weeks of treatment. (<em>see Clinical studies</em>).&nbsp; For the treatment of patients who are coinfected with HIV and are currently receiving or are planning to receive an antiretroviral treatment regimen including lamivudine, the dose of lamivudine usually prescribed for HIV infection should be maintained.</p><p>&nbsp;</p><p>&nbsp;There is limited&nbsp; information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with ZEFFIX. The standard recommended procedures for hepatitis B virus immunisation in infants should be followed.</p><p>&nbsp;Patients should be advised that therapy with ZEFFIX has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken.</p><p>&nbsp;</p><p><em>Oral solution</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_733aa935-2bfa-4af0-9727-754e6bae7975 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-end'></span></i><![endif]--></p><p>&nbsp;Diabetic patients should be advised that each dose of oral solution (100&nbsp;mg = 20&nbsp;ml) contains 4&nbsp;g of sucrose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged drug.</p><p>&nbsp;ZEFFIX is predominantly eliminated by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other drugs (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with ZEFFIX.</p><p>Drugs shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with <em>ZEFFIX</em>.</p><p><em>&nbsp;</em></p><p><em>Interactions relevant to lamivudine</em></p><p><em>&nbsp;</em></p><p><em>Trimethoprim/sulphamethoxazole: </em>Administration of trimethoprim/sulphamethoxazole 160&nbsp;mg/800&nbsp;mg increased ZEFFIX exposure by about 40%. ZEFFIX had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole. However, unless the patient has renal impairment, no dosage adjustment of ZEFFIX is necessary.</p><p><em>Zidovudine: </em>A modest increase in Cmax (28%) was observed for zidovudine when administered with ZEFFIX, however overall exposure (AUC) was not significantly altered<em>. </em>Zidovudine had no effect on the pharmacokinetics of<em> ZEFFIX (see Pharmacokinetics</em> ).</p><p><em>Emtricitabine</em>: ZEFFIX may inhibit the intracellular phosphorylation of emtricitabine when the two medicinal products are used concurrently. ZEFFIX is not recommended for use in combination with emtricitabine.</p><p>&nbsp;</p><p><em>Sorbitol</em>: Coadministration of sorbitol solution (3.2&nbsp;g, 10.2&nbsp;g, 13.4&nbsp;g) with a single 300&nbsp;mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC&yen;) and 28%, 52%, and 55% in the Cmax of &nbsp;lamivudine in adults. When possible, avoid use of lamivudine with sorbitol-containing medicines or consider more frequent monitoring of HBV viral load when chronic coadministration cannot be avoided.</p><p><em>Alpha-interferon</em>: ZEFFIX has no pharmacokinetic interaction with alpha-interferon when the two drugs are concurrently administered. There were no observed clinically significant adverse interactions in patients taking ZEFFIX concurrently with commonly used immunosuppressant drugs (e.g. cyclosporin A). However, formal interaction studies have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>Reproductive studies in animals have shown no effect on male or female fertility.</p><p><strong>Pregnancy</strong></p><p>Lamivudine has been evaluated in the Antiretroviral Pregnancy Registry in over 11,000 women during pregnancy and postpartum.&nbsp; Less than 1% of these women have been treated for HBV, whereas the majority was treated for HIV at higher doses and with other concomitant HIV medications. Available human data from the Antiretroviral Pregnancy Registry do not show an increased risk of major birth defects for lamivudine compared to the background rate (see Clinical Studies).&nbsp; However, there are no adequate and well-controlled trials in pregnant women and the safe use of lamivudine in human pregnancy has not been established.</p><p>Studies in humans have confirmed that <em>ZEFFIX</em> crosses the placenta.</p><p>&nbsp;Use in pregnancy should be considered only if the benefit outweighs the risk. Although the results of animal studies (<em>see Pre-clinical safety data</em>) are not always predictive of human response, there was no evidence of teratogenicity in animals but, findings in rabbit suggest a potential risk of early embryonic loss that was not observed in the rat. For patients who are being treated with ZEFFIX and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of ZEFFIX (<em>see Warnings and Precautions</em>).</p><p><strong>Lactation</strong></p><p>Following repeat oral administration of either 150&nbsp;mg or 300&nbsp;mg, lamivudine twice daily, lamivudine was excreted in human breast milk (0.5 to 8.2 micrograms/ml) at similar concentrations to those found in serum.&nbsp; In other studies, following repeat oral administration of 150&nbsp;mg lamivudine twice daily the breast milk: maternal plasma ratio ranged between 0.6 and 3.3.&nbsp; Lamivudine median infant serum concentrations ranged between 18 and 28 ng/mL and were not detectable in one of the studies (assay sensitivity 7 ng/mL).&nbsp; The clinical relevance of this finding is unknown.</p><p>Data from animal studies in which neonatal rats received <em>ZEFFIX</em> at much higher concentrations via maternal milk suggest that the concentrations of lamivudine in human breast milk are unlikely to produce toxicity in breast fed infants.</p><p>ZEFFIX should only be used in a nursing mother if the expected benefit justifies the potential risk to the infant. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEFFIX therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of ZEFFIX on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities would not be predicted from the pharmacology of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Trial Data</strong></p><p>&nbsp;In clinical studies of patients with chronic hepatitis B, ZEFFIX was well tolerated. The incidence of adverse events and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and ZEFFIX treated patients (see Table 3). The most common adverse events reported were malaise and fatigue, respiratory tract infections, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.</p><p>Table 3.<!--[if supportFields]><span
style='mso-fareast-language:EN-GB;font-weight:normal'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_f5a9d41f-9908-4752-be87-0262544cca5f
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-fareast-language:EN-GB;font-weight:normal'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse event</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Clinical trial data: </strong></p><p><strong>Integrated phase III data </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo (n=200)</strong></p></td><td style="vertical-align:top"><p><strong><em>ZEFFIX</em> 100&nbsp;mg (n=416)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Malaise &amp; Fatigue</strong></p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>26%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory tract infection</strong></p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Headache</strong></p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>22%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Abdominal discomfort &amp; pain</strong></p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nausea &amp; vomiting</strong></p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>16%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT</strong><strong> elevations during treatment</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
  8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span style='mso-element:field-end'></span></b><![endif]--></p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT</strong><strong> elevations post treatment</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
  8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span style='mso-element:field-end'></span></b><![endif]--><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
  8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span style='mso-element:field-end'></span></b><![endif]--></p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Elevated CPK</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
  8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span style='mso-element:field-end'></span></b><![endif]--></p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>9%</p></td></tr></tbody></table><p><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-element:field-end'></span></b><![endif]-->Percentage of patients experiencing a grade III or IV laboratory abnormality during treatment.</p><p><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-element:field-end'></span></b><![endif]--><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span>SYMBOL
8224\u</b><![endif]--><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-element:field-end'></span></b><![endif]-->Percentage of patients experiencing a grade III or IV elevation in ALT post-treatment.</p><p>Adverse reactions are listed below by system organ class and frequency. Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to <em>ZEFFIX</em>. Frequencies are defined as: very common (<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->1/10), common (<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->1/100<strong><em> to</em><s>,</s></strong> &lt;1/10), uncommon (<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->1/1000<strong><em> to</em><s>,</s></strong> &lt;1/100), rare (<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->1/10,000<strong><em> to</em><s>,</s></strong> &lt;1/1000) and very rare (&lt;1/10,000).</p><p>The frequency categories assigned to the adverse reactions below are estimates for most events, suitable data for calculating incidence are not available. Very common and common adverse drug reaction frequency categories were determined from clinical trial data and the background incidence in placebo groups was not taken into account. Adverse drug reactions identified through post-marketing surveillance were categorised as rare or very rare.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>&nbsp;Elevations of ALT</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;Elevations in ALT were more common post-treatment in patients treated with ZEFFIX than placebo. In controlled trials in patients with compensated liver disease, however, there was no appreciable difference post treatment in clinically severe ALT elevations associated with bilirubin elevations and / or signs of hepatic insufficiency, between ZEFFIX and placebo treated patients. The relationship of these recurrent hepatitis events to ZEFFIX treatment or to the previous underlying disease is uncertain (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorder</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash<strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong></p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;Elevations of CPK</p></td></tr></tbody></table><p>&nbsp;</p><p>Post Marketing Data</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:652px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of ZEFFIX.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;Thrombocytopenia.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;Muscle disorders, including myalgia and cramps</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Rhabdomyolysis.</p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or parasthesia) have been reported, although no relationship to treatment with lamivudine (EPIVIR) has been clearly established. In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and ZEFFIX treated patients.</p><p>Cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of combination nucleoside analogue therapy in patients with HIV. There have been occasional reports of these adverse events in hepatitis B patients with decompensated liver disease, however there is no evidence that these events were related to treatment with ZEFFIX.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Reporting Hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: : https://ade.sfda.gov.sa</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email:<u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p><p>For any information about this medicinal product, please contact:</p><p>GlaxoSmithKline - Head Office, Jeddah</p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/&nbsp;</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of <em>ZEFFIX</em> at very high dose levels in acute animal studies did not result in any organ toxicity. Limited data are available on the consequences of ingestion of acute overdoses in humans. No fatalities occurred, and the patients recovered. No specific signs or symptoms have been identified following such overdose.</p><p>&nbsp;If overdose occurs the patient should be monitored, and standard supportive treatment applied as required. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group <!--[if supportFields]><span style='mso-element:field-begin'></span>SYMBOL
8722\u<![endif]--><!--[if supportFields]><span style='mso-element:field-end'></span><![endif]--> nucleoside analogue; <strong>ATC Code:</strong> J05A F05.</p><p>&nbsp;</p><p><em>ZEFFIX</em> is an antiviral agent which is highly active against hepatitis B virus in all cell lines tested and in experimentally infected animals.</p><p>&nbsp;</p><p>Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound. The intracellular half-life of the triphosphate in hepatocytes is 17 to 19 h <em>in vitro</em>. Lamivudine-TP acts a substrate for the HBV viral polymerase. The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination</p><p>&nbsp;</p><p>Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism. It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta. Furthermore, lamivudine-TP has little effect on mammalian cell DNA content.</p><p>&nbsp;</p><p>In assays relating to potential drug effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects. It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase <!--[if supportFields]><span style='mso-element:field-begin'></span>SYMBOL
947\u<![endif]--><!--[if supportFields]><span style='mso-element:field-end'></span><![endif]-->.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85%. Following oral administration, the mean time (t<sub>max</sub>) to maximal serum concentrations (C<sub>max</sub>) is about an hour. At therapeutic dose levels i.e. 100&nbsp;mg once daily, C<sub>max</sub> is in the order of 1.1 to 1.5&nbsp;micrograms/ml and trough levels were 0.015 to 0.020&nbsp;micrograms/ml.</p><p>&nbsp;</p><p>Co-administration of <em>ZEFFIX</em> with food resulted in a delay of t<sub>max </sub>and a lower C<sub>max</sub> (decreased by up to 47%). However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore <em>ZEFFIX</em> can be administered with or without food.</p><p>&nbsp;</p><p>Distribution</p><p>From i.v. studies the mean volume of distribution is 1.3&nbsp;L/kg. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding to albumin.</p><p>&nbsp;</p><p>Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF). The mean lamivudine CSF/serum concentration ratio 2 to 4 hours after oral administration was approximately 0.12.</p><p>&nbsp;</p><p>Metabolism</p><p>Lamivudine is predominately cleared by renal excretion of unchanged drug. The likelihood of metabolic drug interactions with lamivudine is low due to the small (5 to 10%) extent of hepatic metabolism and the low plasma protein binding.</p><p>&nbsp;</p><p><em>Effect of other agents on the pharmacokinetics of lamivudine </em></p><p><em>&nbsp;</em></p><p>Lamivudine is a substrate of MATE1, MATE2-K and OCT2 in vitro. Trimethoprim (an inhibitor of these drug transporters) when given in combination with sulphamethoxazole, has been shown to increase lamivudine plasma concentrations (See Interactions).</p><p>&nbsp;</p><p>Lamivudine is a substrate of the hepatic uptake transporter OCT1.&nbsp; As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance.</p><p>&nbsp;</p><p>Lamivudine is an in vitro substrate of Pgp and BCRP, however due to its high bioavailability it is unlikely that these transporters play a significant role in the absorption of lamivudine.&nbsp; Therefore co-administration of drugs that are inhibitors of these efflux transporters is unlikely to affect the disposition and elimination of lamivudine.</p><p>&nbsp;</p><p><em>Effect of lamivudine on the pharmacokinetics of other agents </em></p><p><em>&nbsp;</em></p><p>In vitro, lamivudine demonstrates no or weak inhibition of the drug transporters organic anion transporter 1B1 (OATP1B1), OATP1B3, breast cancer resistance protein (BCRP) or P-glycoprotein (Pgp), multidrug and toxin extrusion protein 1 (MATE1), MATE2-K or organic cation transporter 3 (OCT3). Lamivudine is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.</p><p>&nbsp;</p><p>Lamivudine is an inhibitor of OCT1 and OCT2 in vitro with IC50 values of 17 and 33 uM, respectively, however lamivudine has low potential to affect the plasma concentrations of OCT1 and OCT2 substrates at therapeutic drug exposures (up to 300 mg which is three times higher than the recommended maximum dose for HBV).</p><p>&nbsp;</p><p>Elimination</p><p>The mean systemic clearance of lamivudine is approximately 0.3&nbsp;L/h/kg. The observed half-life of elimination is 5 to 7 hours. The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system).</p><p>Renal clearance accounts for about 70% of lamivudine elimination.</p><p>&nbsp;</p><p>Special Patient Populations</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8226\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_07d762c8-cbc3-45da-8410-14dae9188de7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>In paediatric patients lamivudine pharmacokinetics are generally similar to adults.&nbsp; However, weight-corrected oral clearances were higher in children resulting in lower AUCs than adults.&nbsp; Age-stratified oral clearance was highest at age 2 and declined from 2 to 12 years, where values were then similar to those seen in adults.&nbsp; A dose of 3&nbsp;mg/kg given once daily produced a steady-state lamivudine AUC similar to that associated with a dose of 100&nbsp;mg/day in adults. The recommended dose for children from 2 to eleven years of age is 3&nbsp;mg/kg once daily up to a maximum of 100&nbsp;mg daily which will provide comparable exposure to the adult recommended dose (100&nbsp;mg once a day).&nbsp; There are limited pharmacokinetic data for patients less than 2 years of age.</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8226\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a95a9d1b-47c3-410b-a4cc-2e6fbcddf6e4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of less than 50&nbsp;ml/min. (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8226\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7c2ca217-f206-4e00-83c4-6e780399bc3b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Dose reduction in patients with a creatinine clearance of less than 50&nbsp;ml/min is necessary (<em>see</em> <em>Dosage and Administration</em>).</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8226\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ae251157-20eb-4b3e-83aa-34672173975d \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>A study in hepatically impaired patients (non-HIV and non-HBV infected) showed <em>ZEFFIX</em> is well tolerated in this patient group with no changes in laboratory parameters or the adverse event profile of <em>ZEFFIX</em>. The pharmacokinetics of lamivudine are unaffected by hepatic impairment.</p><p>Limited data in patients undergoing liver transplantation show that impairment of hepatic function does not impact significantly on the pharmacokinetics of lamivudine unless accompanied by renal dysfunction.</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 8226\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1534e02f-b486-4407-8095-b65b41757bd1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Following oral administration, lamivudine pharmacokinetics in late pregnancy were similar to non-pregnant adults.</p><p>Lamivudine concentrations in infant serum at birth were similar to those in maternal and cord serum at delivery.</p><p>&nbsp;</p><p>Clinical Studies</p><p><em>ZEFFIX</em> has potent anti-viral activity <em>in vivo</em>, rapidly suppressing HBV replication following initiation of treatment resulting in continued HBV suppression, normalisation of serum aminotransferase, significant reductions in liver necro-inflammatory activity, reduced progression of fibrosis and increased HBeAg seroconversion. <em>ZEFFIX</em> has been administered to chronic hepatitis B patients for up to four years in clinical studies.&nbsp; Similar results have been seen in patients regardless of ethnic origin.</p><p>&nbsp;</p><p>In controlled studies in over 800 HBeAg positive patients, treatment with <em>ZEFFIX</em> for one year significantly suppressed HBV DNA replication (34 to 57% of patients), normalised ALT levels (40 to 72% of patients), induced HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection, 16 to 18% of patients), improved histology (38 to 52% of patients), and reduced progression of fibrosis (3 to 17% of patients) and progression to cirrhosis (1.8% of patients).</p><p>The HBeAg seroconversion was maintained in 81% (34/42) of patients off drug followed for approximately two years.&nbsp; In addition, HBsAg seroconversion was achieved in 21% (9/42) patients.</p><p>In HBeAg positive patients who had not experienced HBeAg seroconversion in one-year controlled studies and were subsequently treated with 2 years of <em>ZEFFIX</em>, 77/128 (60%) had improvement in liver inflammation and 26/51 (51%) had improvement in bridging fibrosis.</p><p>In an additional study, after four years of <em>ZEFFIX</em> therapy HBeAg seroconversion (HBeAg loss and HBeAb detection) was seen in 47% (27/58) patients (59% [24/41] of patients with abnormal baseline ALT).</p><p>&nbsp;</p><p>In patients who have not HBeAg seroconverted during treatment, discontinuation of <em>ZEFFIX</em> results in a return of HBV replication with both HBV DNA and serum aminotransferases returning towards pre-treatment levels within 2 to 6 months.</p><p>&nbsp;</p><p>In patients followed for up to 16&nbsp;weeks after discontinuation of treatment, post-treatment ALT elevations were observed more frequently in patients who had received <em>ZEFFIX</em> than in patients who had received placebo. A comparison of ALT elevations between weeks 52 and 68 in patients who discontinued <em>ZEFFIX</em> at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table&nbsp;4.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4: Post-treatment ALT Elevations in 2 Placebo-Controlled Studies in Adults with No-Active-Treatment Follow-up.</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Abnormal Value</p></td><td colspan="2" style="vertical-align:top"><p>Patients with ALT Elevation/</p><p>Patients with Observations<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>ZEFFIX</em></p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>ALT <!--[if supportFields]><span
  style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
  style='mso-element:field-end'></span><![endif]-->2 x baseline value</p></td><td style="vertical-align:top"><p>37/137 (27%)</p></td><td style="vertical-align:top"><p>22/116 (19%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT <!--[if supportFields]><span
  style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
  style='mso-element:field-end'></span><![endif]-->3 x baseline value<!--[if supportFields]><sup><span
  style='mso-element:field-begin'></span>SYMBOL 8224\u</sup><![endif]--><!--[if supportFields]><sup><span
  style='mso-element:field-end'></span></sup><![endif]--></p></td><td style="vertical-align:top"><p>29/137 (21%)</p></td><td style="vertical-align:top"><p>9/116 (8%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT <!--[if supportFields]><span
  style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
  style='mso-element:field-end'></span><![endif]-->2 x baseline value and absolute ALT &gt;500&nbsp;IU/L</p></td><td style="vertical-align:top"><p>21/137 (15%)</p></td><td style="vertical-align:top"><p>8/116 (7%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT <!--[if supportFields]><span
  style='mso-element:field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
  style='mso-element:field-end'></span><![endif]-->2 x baseline value; and bilirubin &gt;2 x ULN and <!--[if supportFields]><span style='mso-element:
  field-begin'></span>SYMBOL 8805\u<![endif]--><!--[if supportFields]><span
  style='mso-element:field-end'></span><![endif]-->2 x baseline value&nbsp;</p></td><td style="vertical-align:top"><p>1/137 (0.7%)</p></td><td style="vertical-align:top"><p>1/116 (0.9%)</p></td></tr></tbody></table><p><sup>#</sup>Each patient may be represented in one or more category.</p><p><!--[if supportFields]><sup><span
style='mso-element:field-begin'></span>SYMBOL 8224\u</sup><![endif]--><!--[if supportFields]><sup><span
style='mso-element:field-end'></span></sup><![endif]-->Comparable to a Grade 3 toxicity in accordance with modified WHO criteria.</p><p>ULN = Upper limit of normal.</p><p>&nbsp;</p><p>In a placebo-controlled study of 286 hepatitis B patients aged 2 to 17 years, patients treated with <em>ZEFFIX</em> for one year had a significantly better complete virological response (loss of HBeAg and HBV DNA) compared with patients receiving placebo (23% [44/191] vs 13% [12/95]). Normalisation of serum ALT was more frequent in patients treated with <em>ZEFFIX</em> compared with placebo (55% [100/183] vs 13% [11/88]). In a stratified follow-on study for six months, complete virological response was maintained in 83% [33/40] of patients who had responded after one year of treatment with <em>ZEFFIX</em> and then stopped therapy.&nbsp; <em>ZEFFIX</em> treated patients who did not respond after one-year continued treatment for a further 6 months resulting in an additional 10% (12/123) of patients achieving virological response and a cumulative complete virological response of 28% (45/163) over 18 months.</p><p>&nbsp;</p><p>HBV viral sub-populations with reduced susceptibility to <em>ZEFFIX</em> <em>in vitro</em> have been identified. These HBV variants (YMDD variant HBV) are also found in hepatitis B patients who experience a return of detectable serum HBV DNA levels whilst on <em>ZEFFIX</em> treatment. The incidence of YMDD variant HBV (<em>see Warnings and Precautions</em>), as detected by polymerase chain reaction, increases with duration of treatment; 20% after one year, 53% after three years, 70% after four years and may be higher in immunocompromised patients.</p><p>&nbsp;</p><p>Despite the emergence of YMDD variant HBV, patients treated for one year had significantly lower serum HBV DNA and ALT levels and improved liver histology compared to patients on placebo. After 2 years of <em>ZEFFIX</em> treatment, the majority of patients with YMDD variant HBV maintained serum HBV DNA and ALT levels lower than their pre-treatment values and a proportion experienced HBeAg seroconversion. The adverse event profile is similar for patients with or without YMDD variant HBV.</p><p>&nbsp;</p><p>Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment. (<em>see Warnings and Precautions</em>). In patients with HBeAg negative chronic hepatitis B, the efficacy of <em>ZEFFIX</em> was similar to those infected with wild type HBV (e.g. 71% of patients with HBV DNA suppression, 67% with ALT normalisation and 38% with Knodell HAI-score improvement at one year on treatment).&nbsp; If therapy with <em>ZEFFIX</em> is stopped after one year of treatment, the majority of patients with HBeAg negative chronic hepatitis B have a return of viral replication. Limited data indicate that extended <em>ZEFFIX</em> treatment (two years) maintains HBV DNA suppression and ALT normalisation in this patient population. The incidence of serious adverse events at any time during and post-treatment was low and similar in patients with HBeAg negative chronic hepatitis B with or without YMDD variant HBV.</p><p>&nbsp;</p><p>In non-controlled studies in liver transplant patients in which <em>ZEFFIX</em> was administered prior to and during transplantation, effective HBV DNA suppression and ALT normalisation was demonstrated.&nbsp; When <em>ZEFFIX</em> therapy was continued post-transplantation there was reduced graft re-infection by HBV, increased HBsAg loss, and a one-year survival rate of 76 to 100%.&nbsp; These studies were not placebo-controlled as this was regarded inappropriate in patients with decompensated liver disease.</p><p>As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD variant HBV after 52 weeks treatment was higher (36% to 64%) in liver transplant patients compared with immunocompetent chronic hepatitis B patients (14% to 32%).&nbsp; Studies provide evidence however that the emergence of YMDD variant is not consistently associated with hepatic disease progression and that the majority of patients may continue to benefit from continued <em>ZEFFIX</em> therapy.&nbsp;</p><p>Studies of monotherapy with <em>ZEFFIX</em> compared to alpha-interferon alone or in combination for treatment of chronic hepatitis B patients showed no significant difference in histologic response or HBeAg seroconversion rates between the treatment groups. The safety profile of <em>ZEFFIX</em> was superior to the alpha-interferon containing treatment regimens.</p><p>&nbsp;</p><p>There is no clinical data on the efficacy of <em>ZEFFIX</em> in patients co-infected with Delta hepatitis.</p><p>&nbsp;</p><p>The Antiretroviral Pregnancy Registry has received reports of over 11,000 exposures to lamivudine during pregnancy resulting in live birth, less than 1% of which were in patients with HBV. These consist of over 4,500 exposures during the first trimester, over 7,200 exposures during the second/third trimester and included 143 and 207 major birth defects respectively. The prevalence (95% CI) of defects in the first trimester was 3.1% (2.6, 3.7%) and in the second/third trimester, 2.9% (2.5, 3.3%). Among pregnant women in the reference population, the background rate of birth defects is 2.7%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of <em>ZEFFIX</em> in animal toxicity studies at high doses was not associated with any major organ toxicity. At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights. Reduction of erythrocytes and neutrophil counts were identified as the effects most likely to be of clinical relevance. These events were seen infrequently in clinical studies.</p><p>Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an <em>in vitro</em> cytogenetic assay and the mouse lymphoma assay. Lamivudine was not genotoxic <em>in vivo</em> at doses that gave plasma concentrations around 60 to 70 times higher than the anticipated clinical plasma levels. As the <em>in vitro</em> mutagenic activity of <em>ZEFFIX</em> could not be confirmed by <em>in vivo</em> tests, it is concluded that <em>ZEFFIX</em> should not represent a genotoxic hazard to patients undergoing treatment.</p><p>The results of long-term carcinogenicity studies with <em>ZEFFIX</em> in rats and mice did not show any carcinogenic potential.</p><p>Reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility in rats. Lamivudine produced small increases in early embryonic loss when administered to pregnant rabbits, at exposure levels comparable to those achieved in man. However, there was no evidence of embryonic loss in rats at exposure levels of approximately 60 times the clinical exposure (based on C<sub>max</sub>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p>Sucrose (20% w/v).<em> (see Warnings and Precautions)</em></p></td></tr><tr><td style="vertical-align:top"><p>Methyl parahydroxybenzoate.</p></td></tr><tr><td style="vertical-align:top"><p>Propyl parahydroxybenzoate.</p></td></tr><tr><td style="vertical-align:top"><p>Citric acid (anhydrous).</p></td></tr><tr><td style="vertical-align:top"><p>Propylene glycol.</p></td></tr><tr><td style="vertical-align:top"><p>Sodium citrate.</p></td></tr><tr><td style="vertical-align:top"><p>Artificial strawberry flavour.</p></td></tr><tr><td style="vertical-align:top"><p>Artificial banana flavour.</p></td></tr><tr><td style="vertical-align:top"><p>Purifed water.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at or below 25<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 176\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons containing 240&nbsp;ml <em>ZEFFIX</em> oral solution 5&nbsp;mg/ml in an opaque, white high-density polyethylene (HDPE) bottle with a polypropylene child resistant closure. The pack includes a clear oral dosing syringe and an adapter.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An oral dosing syringe is provided for accurate measurement of the prescribed dose of oral solution.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Use the oral dosing syringe supplied with the pack to measure the correct dose of ZEFFIX </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the bottle cap. Keep it safely.</em></strong></p><p><strong><em>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the bottle firmly. Push the plastic adapter into the neck of the bottle. </em></strong></p><p><strong><em>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe firmly into the adapter.</em></strong></p><p><strong><em>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle upside down.</em></strong></p><p><strong><em>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull out the syringe plunger until the syringe contains the first part of your full dose. </em></strong></p><p><strong><em>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle the correct way up. Remove the syringe from the adapter.</em></strong></p><p><strong><em>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the syringe into your mouth, placing the tip of the syringe against the inside of your cheek. Slowly push the plunger in, allowing time to swallow. Don&rsquo;t push too hard and squirt the liquid into the back of your throat or you may choke. </em></strong></p><p><strong><em>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps 3 to 7 in the same way until you have taken your whole dose. For example, if your dose is 15&nbsp;ml, you need to take one and a half syringe-full of medicine.</em></strong></p><p><strong><em>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the syringe out of the bottle and wash it thoroughly in clean water. Let it dry completely before you use it again.</em></strong></p><p><strong><em>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle tightly with the cap, leaving the adaptor in place.</em></strong></p><p>Discard oral solution one month after first opening.</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p><p>&nbsp;</p><p><em>ZEFFIX</em> is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2021 GlaxoSmithKline, all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Bora Pharmaceutical Services Inc. Mississauga, Canada

Packed by: 
Bora Pharmaceutical Services Inc. Mississauga, Canada

Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia

*member of the GlaxoSmithKline group of companies
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS17/IPI09
Date of issue:  06 July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>